Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Rodman & Renshaw starts Hemab Therapeutics at buy; PT $56

Rodman & Renshaw initiated coverage of Hemab Therapeutics (NASDAQ: COAG) with a “buy” rating and price target of $56.00. The stock closed at $31.62 on October 9. Hemab’s lead asset sutacimig is a bispecific...

October 13, 2026

Developments

Profound Medical and Telix Pharmaceuticals enter co-education agreement to advance PSMA-informed, MRI-guided and incisionless prostate care

Profound Medical (NASDAQ:PROF; TSX:PRN) and Telix Pharmaceuticals (ASX:TLX; NASDAQ:TLX) have entered into a co-education agreement which establishes a framework through which the companies intend to educate urologists...

October 9, 2026

Developments

As AI powers a U.S. nuclear buildout, Valion’s needle-free Entolimod could bring radiation preparedness to population scale

Rising electricity demand from AI and data centers is driving plans to expand nuclear power capacity, possibly including on-site small modular reactors (SMRs). This made international headlines earlier this week as...

October 9, 2026

Developments

Co-Diagnostics announces first Vector Smart lab for Native American tribe

Co-Diagnostics (NASDAQ: CODX) has announced that it has received an order from the Ute Indian Tribe Mosquito Abatement Department for a full Vector Smart mosquito surveillance laboratory installation. According to Co...

October 8, 2026

Developments

JPO issues NOA for bioAffinity’s CyPath Lung patent

bioAffinity Technologies (NASDAQ: BIAF) has announced that the Japan Patent Office (JPO) has issued a notice of allowance (NOA) indicating its intention to grant a patent covering bioAffinity’s non-invasive lung cancer...

October 8, 2026

Developments

Profound reports record preliminary Q3-2026 revenue; expects up to 89% YoY and 300% sequential QoQ growth; preliminary numbers exceed Bloomberg analyst consensus by 45% to 47%

Profound Medical (NASDAQ: PROF; TSX: PRN) announced preliminary unaudited revenues for the third quarter of 2026. The company indicated that its: Total revenue is expected to be in the range of $9.8 million to $10.0...

October 8, 2026

Developments

RenovoRx advances TAMP into borderline resectable PDAC

RenovoRX (NASDAQ: RNXT) has announced that the first patient has enrolled in PRISM-TAMP, an investigator-initiated trial sponsored by the University of Vermont (UVM) evaluating the approved chemotherapy gemcitabine...

October 7, 2026

Developments

PacBio and TychoBio collaborate to train AI models for rare disease therapeutics

PacBio (NASDAQ: PACB) and closely held TychoBio have announced a collaboration to generate full-length RNA data that TychoBio will use to train models for RNA therapy design. Under the terms of the agreement, TychoBio...

October 6, 2026

Developments

Saluda announces U.S. availability of first and only closed-loop surgical paddle

Saluda Medical (ASX: SLD) has announced the full U.S. commercial release of the FDA-approved CAP24 Surgical Paddle Lead making it available to neurosurgery and orthopedic spine practices in selected centers...

October 6, 2026

Developments

Wandercraft acquires Esko Bionics advancing robotic mobility

Closely held Wandercraft has announced the acquisition of Ekso Bionics from a subsidiary of ChronoScale Holdings Corporation (NASDAQ: CHRN), uniting two leaders in robotic mobility to form the world’s leading medical...

October 2, 2026

Developments

FDA clears IND application for Surrozen’s SZN-8141 in DME

Surrozen (NASDAQ: SRZN) has announced its Investigational New Drug (IND) application for SZN-8141 for the treatment of diabetic macular edema (DME) has become effective, enabling advancement to clinical development. SZN...

October 2, 2026

Developments

Tenon launches titanium 3D-printed lateral screw

Tenon Medical (NASDAQ: TNON) has announced the full commercial launch of its new titanium 3D-printed lateral screw as part of the SImmetry+ SI Joint Fusion System following the successful completion of the...

September 30, 2026

Developments

Connect reports positive data from study of rademikibart in COPD

Connect Biopharma (NASDAQ: CNTB) has announced topline results from its global Phase 2 study evaluating rademikibart, its next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody as...

September 30, 2026

Developments

Valion sees potential for multi-fold expansion of long-term opportunity after successful joint formulation of oral mucosal Entolimod for acute radiation syndrome

Valion Bio (NASDAQ: VBIO) and closely held Shear Kershman Laboratories (SKL) announced the successful completion of formulation work under the companies’ ongoing program to develop a novel oral mucosal formulation of...

September 30, 2026

Developments

Immix reports 89% CR in trial of NXC-201 in R/R AL amyloidosis

Immix Biopharma (NASDAQ: IMMX) has reported interim data showing an 89% complete response (CR) rate across all 45 enrolled patients, based on an assessment by an independent review committee, from its NEXICART-2 Phase 2...

September 29, 2026

Developments

Codexis enters agreement with drug innovator to create stereo-defined siRNA

Codexis (NASDAQ: CDXS) has announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis Manufacturing Platform. According to Codexis, the agreement...

September 28, 2026

Developments

DataMeds AI and Tollo Health announce mobile app

DataMeds AI (NASDAQ: MEDS) and closely held Tollo Health have announced the launch of the Health Lives Here mobile application (app), initially focused on supporting users of GLP-1 receptor agonist medications...

September 28, 2026

Developments

Firefly and NeuroSigma partner to expand access to first FDA-cleared non-drug for pediatric ADHD

Firefly Neuroscience (NASDAQ: AIFF) has announced a strategic partnership to expand clinician awareness of and access to NeuroSigma’s Monarch eTNS System, the first FDA-cleared non-drug for pediatric attention...

September 25, 2026

Developments

NeuroThera expands IP portfolio through collaboration with Clearmind

NeuroThera Labs (TSXV: NTLX) has highlighted the expansion of the U.S. intellectual property (IP) portfolio through its ongoing collaboration with Clearmind Medicine (NASDAQ: CMND). As part of the collaboration, three U...

September 24, 2026

Developments

MAIA expands pivotal Phase 3 study of THIO-104 in NSCLC

MAIA Biotechnology (NYSE American: MAIA) has received regulatory approval by the Spanish Agency for Medicines and Medical Devices and Portugal’s National Authority of Medicines and Health Products to begin...

September 24, 2026

Developments

Medicus to focus SkinJect on Gorlin syndrome patients

Medicus Pharma (NASDAQ: MDCX) has announced it will focus SkinJect development exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions and will conclude further development in sporadic/nodular...

September 22, 2026

Developments

Profound Medical’s new president makes open market purchase of company shares

According to a filing with SEDI, Profound Medical (NASDAQ:PROF; TSX:PRN) president, Richard Fabian, acquired a total of 10,000 shares of Profound on the open market today at a cost of $59,800 (U.S.). In a sign of...

September 17, 2026

Subscribe